- Home
- DMA vs NSPR Comparison
DMA vs NSPR Comparison
Compare DMA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | NSPR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 77.5M |
| IPO Year | 2011 | 2009 |
Fundamental Metrics
Financial Performance| Metric | DMA | NSPR |
|---|---|---|
| Price | $8.19 | $1.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 44.3K | 23.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $22.91 |
| Revenue Next Year | N/A | $72.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.17 | $1.51 |
| 52 Week High | $9.15 | $3.34 |
Technical Indicators
Market Signals| Indicator | DMA | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 42.23 |
| Support Level | N/A | $1.56 |
| Resistance Level | $8.87 | $2.51 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 31.21 | 21.70 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.